The latest price target for Novo Nordisk (NYSE:NVO) was reported by BMO Capital on April 17, 2025. The analyst firm set a price target for $64.00 expecting NVO to fall to within 12 months (a possible -6.79% downside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Novo Nordisk (NYSE:NVO) was provided by BMO Capital, and Novo Nordisk downgraded their market perform rating.

The last upgrade for Novo Nordisk AS happened on January 8, 2025 when UBS raised their price target to N/A. UBS previously had a sell for Novo Nordisk AS.

The last downgrade for Novo Nordisk AS happened on April 17, 2025 when BMO Capital changed their price target from $105 to $64 for Novo Nordisk AS.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novo Nordisk, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novo Nordisk was filed on April 17, 2025 so you should expect the next rating to be made available sometime around April 17, 2026.

While ratings are subjective and will change, the latest Novo Nordisk (NVO) rating was a downgraded with a price target of $105.00 to $64.00. The current price Novo Nordisk (NVO) is trading at is $68.66, which is out of the analyst’s predicted range.